Mark G Kris Selected Research

Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar)

5/2011	Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
3/2008	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
1/2008	Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
11/2006	Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
10/2005	How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
1/2005	Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
11/2004	SCCRO expression correlates with invasive progression in bronchioloalveolar carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark G Kris Research Topics

Disease

135	Neoplasms (Cancer) 11/2022 - 02/2002
108	Lung Neoplasms (Lung Cancer) 01/2022 - 03/2003
67	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 02/2001
59	Adenocarcinoma of Lung 01/2021 - 01/2005
15	Adenocarcinoma 01/2019 - 03/2004
14	Neoplasm Metastasis (Metastasis) 11/2022 - 11/2002
13	Disease Progression 01/2021 - 05/2005
13	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2018 - 02/2003
11	Brain Neoplasms (Brain Tumor) 01/2022 - 11/2002
9	Nausea 01/2018 - 10/2002
8	Breast Neoplasms (Breast Cancer) 01/2020 - 02/2002
8	Vomiting 10/2017 - 10/2002
7	Fatigue 01/2018 - 05/2005
7	Carcinoma (Carcinomatosis) 06/2014 - 07/2002
7	Bronchiolo-Alveolar Adenocarcinoma (Adenocarcinoma, Bronchiolo Alveolar) 05/2011 - 11/2004
5	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 02/2007
5	Stomatitis 08/2007 - 06/2003
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019 - 05/2004
4	Exanthema (Rash) 01/2018 - 09/2005
4	Edema (Dropsy) 01/2016 - 06/2003
3	Hypersensitivity (Allergy) 01/2021 - 02/2008
3	Malignant Mesothelioma 01/2021 - 04/2007
3	Carcinogenesis 01/2021 - 04/2004
3	Mesothelioma 01/2020 - 09/2003
3	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2019 - 05/2011
3	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 06/2003
3	Neutropenia 10/2018 - 02/2007
3	Thrombocytopenia (Thrombopenia) 10/2018 - 03/2011
3	Diarrhea 01/2018 - 09/2005
3	Neuroblastoma 02/2015 - 02/2010
3	Peripheral Nervous System Diseases (PNS Diseases) 01/2012 - 05/2007
2	Hemorrhage 01/2022 - 12/2010

Drug/Important Bio-Agent (IBA)

63	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2003
48	Tyrosine Kinase InhibitorsIBA 01/2022 - 02/2003
41	Gefitinib (Iressa)FDA Link 12/2014 - 06/2003
36	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 01/2005
17	Pharmaceutical PreparationsIBA 01/2021 - 02/2001
14	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2002
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2010
13	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2007
13	Docetaxel (Taxotere)FDA Link 04/2016 - 02/2001
11	Paclitaxel (Taxol)FDA LinkGeneric 12/2021 - 06/2003
11	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2015 - 10/2003
9	Carboplatin (JM8)FDA LinkGeneric 12/2021 - 06/2003
9	human ERBB2 proteinIBA 12/2019 - 02/2012
9	Cisplatin (Platino)FDA LinkGeneric 04/2016 - 02/2001
8	Phosphotransferases (Kinase)IBA 01/2021 - 01/2005
7	Biological ProductsIBA 01/2022 - 04/2004
6	osimertinibIBA 01/2022 - 01/2018
6	AfatinibIBA 01/2021 - 10/2012
6	Pemetrexed (MTA)FDA Link 01/2017 - 10/2005
5	RNA (Ribonucleic Acid)IBA 01/2021 - 02/2010
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 07/2012
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2020 - 01/2016
5	Bevacizumab (Avastin)FDA Link 01/2020 - 12/2010
5	AntiemeticsIBA 01/2020 - 10/2002
5	PlatinumIBA 01/2020 - 02/2007
5	Anaplastic Lymphoma KinaseIBA 03/2016 - 02/2012
4	Immune Checkpoint InhibitorsIBA 10/2021 - 01/2018
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 02/2005
4	Gemcitabine FDA Link 01/2020 - 06/2003
4	Messenger RNA (mRNA)IBA 01/2019 - 05/2004
4	cabozantinibIBA 10/2018 - 06/2013
4	EmeticsIBA 10/2017 - 02/2005
4	Vinorelbine (Navelbine)FDA LinkGeneric 04/2016 - 02/2003
4	10-propargyl-10-deazaaminopterin FDA Link 11/2011 - 05/2006
3	durvalumabIBA 01/2021 - 01/2020
3	Cytotoxins (Cytolysins)IBA 01/2020 - 09/2003
3	Albumin-Bound Paclitaxel FDA Link 01/2020 - 02/2008
3	CrizotinibIBA 01/2020 - 01/2016
3	Temozolomide (Temodar)FDA LinkGeneric 10/2018 - 02/2012
3	Codon (Codons)IBA 03/2015 - 09/2008
3	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 01/2012 - 02/2004
3	Folic Acid AntagonistsIBA 11/2011 - 06/2003
3	Everolimus FDA Link 10/2010 - 08/2007
2	Protons (Proton)IBA 11/2022 - 01/2021
2	trametinibIBA 01/2022 - 01/2021
2	Cell-Free Nucleic AcidsIBA 01/2021 - 01/2021
2	dacomitinibIBA 01/2021 - 12/2014
2	Formaldehyde (Formol)FDA Link 10/2020 - 01/2011
2	ParaffinIBA 10/2020 - 01/2011
2	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2018
2	cyclo(Arg-Pro) (CI 4)IBA 01/2020 - 05/2011
2	Ado-Trastuzumab EmtansineIBA 01/2020 - 01/2018
2	Alanine Transaminase (SGPT)IBA 01/2018 - 01/2016
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2017 - 02/2016
2	Neurokinin-1 Receptor AntagonistsIBA 10/2017 - 11/2011
2	AnthracyclinesIBA 10/2017 - 02/2016
2	Palonosetron (Aloxi)FDA Link 02/2016 - 03/2011

Therapy/Procedure

78	Therapeutics 01/2022 - 10/2003
54	Drug Therapy (Chemotherapy) 01/2019 - 02/2001
16	Radiotherapy 11/2022 - 07/2002
10	Adjuvant Chemotherapy 10/2019 - 07/2007
7	Immunotherapy 01/2021 - 09/2004
6	Neoadjuvant Therapy 01/2019 - 09/2012
5	Aftercare (After-Treatment) 01/2021 - 03/2008
3	Precision Medicine 11/2014 - 01/2007
2	Craniospinal Irradiation 11/2022 - 01/2021
2	Metastasectomy 01/2019 - 03/2013
2	Retreatment 01/2018 - 10/2011